Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank You:
We have received your below message and will respond as soon as possible:
Message Category: Investor Relations
Message: Dear Mr. Dang, Please accept my congradulations upon your new position with PYTO. I am a long time shareholder with in excess of XXXXX shares. Obviously, I am more than casually interested in the current situation within the company. Therefore, I have the following suggestion: Please issue a PR or letter to shareholders announcing the changes within the company managment stucture. Explain what is currrently the situation re Lattitude and what (if any) progress has been made re delivery system. Further update the China situation with view to the future of the "partnership". Touch upon the departure of Dr. Lynch and Greg Wojak. Give your view of the future prospects and direction of Phyto. Thank you very much, and best wishes going forward.
Every time we close up, I look for news. None today, but,the upside on so few shares being purchased shows the potential explosivness when we do get some news. (eventually)Don't be holding breath waiting. LOL
Buying always mekes me wonder and think someone might know something. Otherwise, why would anyone want this depository for dead $?
Re de new boss man:
Amit Singh Dang
Director, President, Chief Executive Officer, Interim Chief Financial Officer, Treasurer and Secreta
PhytoMedical Technologies, Inc.
Vancouver , BC
Sector: HEALTHCARE / Specialized Health Services
Officer since June 2010
On June 3, 2010, Board of Directors appointed Amit S. Dang to the Company?s Board of Directors. Mr. Dang holds a Bachelors degree (B.B.A.) in Finance from Wayne State University (2003), with advanced academic studies in contract, criminal, civil, and policy law; management, finance, logistics, and strategy; and audit theory; from Michigan State University (2003-2004), The University of Michigan (2004-2006), and the Institute of Internal Auditors (2006-2008), respectively. From May 2005 to August 2005, Mr. Dang was employed as an Accountant at Noir Medical Technologies / Laser Company, and from February 2006 to June 2006, he served as a Business Process and Development Consultant for Sterling Solutions and Systems. From June 2006 to May 2008, Mr. Dang worked as a Risk and Performance Services Consultant at Crowe Horwath, where he specialized in identifying high-risk areas for public and private companies and helped develop and re-engineer core business processes for greater efficiency and control. Since May 2008, Mr. Dang has served as the Managing Director for Infinitus Ventures, facilitating the early incubation, capital funding, and development of client companies. Mr. Dang also served as the Interim President and Chief Executive Officer of HepaLife Technologies, Inc. from October 13, 2009 through May 11, 2010. Mr. Dang was invited to join the Board of Directors due to his experience with public companies in the matters relating to business development, financial reporting and legal compliance. Mr. Dang was appointed the Company?s President and Chief Executive Officer. On June 22, 2010, the Board of Directors appointed Mr. Amit S. Dang to serve as the Company?s Interim CFO, Treasurer, and Secretary. Mr. Dang currently serves as the Company?s President and Chief Executive Officer.
pink, sent this email to IR today;
"DEAR MS ERICKSON,
PLEASE LET ME KNOW WHEN SHAREHOLDERS CAN ANTICIPATE SOME TYPE OF UPDATE FROM THE COMPANY RE THE MOST RECENT CHANGES IN MANAGEMENT.
NOW, IN ADDITION TO THE DEPARTURE OF DR LYNCH, GREG WOJAK AND THE OTHER DIRECTOR HAVE BOTH RESIGNED.
THERE IS NO EXCUSE FOR NOT KEEPING SHAREHOLDERS INFORMED .
I LOOK FWD FROM HEARING FROM YOU."
SUGGEST ANY OTHER INTERESTED SHAREHOLDERS FEEL FREE TO CONTACT IR
BRIANNA ERICKSON
TEL 800 611 3388
E-MAIL BERICKSON@PHYTOMEDICAL.COM
WTF, WE'RE SHAREHOLDERS & ENTITLED TO KNOW WHATS GOING ON.
GLTA
A new General is taking over. Wish I had some clue what the heck is going on.
Everyone appears to be bailing out?????????
Form 8-K for PHYTOMEDICAL TECHNOLOGIES INC
--------------------------------------------------------------------------------
24-Jun-2010
Change in Directors or Principal Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On June 17, 2010, Mr. Raymond Krauss tendered his resignation as a Director and officer of PhytoMedical Technologies, Inc. (the "Company") effective as of that date. Of the 200,000 options previously granted to Mr. Krauss pursuant to the terms of the Stock Option Agreement dated March 15, 2010 (the "Krauss SOA"), none have vested, and accordingly, pursuant to the terms of the Krauss SOA, all of such options have been terminated.
On June 17, 2010, Mr. Greg Wujek tendered his resignation as a Director of the Company effective as of that date. Of the 400,000 options previously granted to Mr. Wujek pursuant to the terms of the Stock Option Agreement dated March 15, 2010 (the "Wujek SOA"), 200,000 have vested (the "Vested Options") in accordance with the terms of the Wujek SOA may be exercised through a date that is 90 days from June 17, 2010. The remaining 200,000 options granted to Mr. Wujek pursuant to the Wujek SOA have not vested and, in accordance with the terms of the Wujek SOA, are terminated.
The resignations of Messrs. Kruass and Wujek were not due to any disagreement between the Company and each of Messrs. Krauss and Wujek.
On June 22, 2010, in order to fill the vacancies created by the resignation of Mr. Krauss, the Board of Directors appointed Mr. Amit S. Dang to serve as the Company's Interim CFO, Treasurer, and Secretary. Mr. Dang currently serves as the Company's President and Chief Executive Officer.
Pink, unfortunately I couldn't find out anything cause IR, Brianna, is about as useful as teats on a bullfrog.
Tried to contact GW on both phone # and Email address I had for him, to no avail.
Guess the only thing left to do is try to call Harmel, and good luck on that.
We is now flying blind with white nuckles on this one now.
Did you ever find a reason for the Lynch and Branning departure and the Dang/Sidhu appointments. From what I see these are Rayat Harmels boys from over at Hepalife -another primary Rayat holding. Not sure if Rayat was not happy with the 200 million increase and how they were handling it or if Lynch and Branning found something out and bailed?????
Is the cancer formualtion still viable for production and what about the China end of things? A PR update would be nice!
If I ever think there are buyers again, please shoot me!!!
FWIW, I called IR (Brianna) a few days ago and she is, unfortunately, unable to say anything of value. She did, however, say PYTO is still involved with Lattitude re the delivery system.
Who ever thought it would take so long.
My worthless idea is to drill a hole in the skull and inject the stuff directly into the tumor. But, what the hell do I know, I'm just an idiot shareholder sitting with dead $ here. (watching other stocks succeed).
PITTER PATTER OF LITTLE FEET BUYING LAST 2 DAYS?????????????????
Hopefully some front running of good news.
Otherwise, back to the doldrums.
NEW NEWS:
On May 31, 2010, Mr. James Lynch tendered his resignation as a Director and as the President and Chief Executive Officer of PhytoMedical Technologies, Inc. (the “ Company ”) effective as of noon on May 31, 2010. The resignation constituted a termination of the employment agreement between Mr. Lynch and the Company dated March 15, 2010 (the “ Lynch Employment Agreement ”). None of the options previously granted to Mr. Lynch pursuant to his Lynch Employment Agreement have vested and the options have been terminated and cancelled.
On June 1, 2010, Mr. Gary Branning tendered his resignation as a Director of the Company effective as of that date.
The resignations of Messrs. Lynch and Branning were not due to any disagreement between the Company and each of Messrs. Lynch and Branning.
On June 3, in order to fill vacancies created by the resignations of Messrs. Lynch and Branning, the Board of Directors appointed each of Messrs. Amit S. Dang and Jeet S. Sidhu to the Company’s Board of Directors.
Mr. Dang holds a Bachelors degree (B.B.A.) in Finance from Wayne State University (2003), with advanced academic studies in contract, criminal, civil, and policy law; management, finance, logistics, and strategy; and audit theory; from Michigan State University (2003-2004), The University of Michigan (2004-2006), and the Institute of Internal Auditors (2006-2008), respectively. From May 2005 to August 2005, Mr. Dang was employed as an Accountant at Noir Medical Technologies / Laser Company, and from February 2006 to June 2006, he served as a Business Process and Development Consultant for Sterling Solutions and Systems. From June 2006 to May 2008, Mr. Dang worked as a Risk and Performance Services Consultant at Crowe Horwath, where he specialized in identifying high-risk areas for public and private companies and helped develop and re-engineer core business processes for greater efficiency and control. Since May 2008, Mr. Dang has served as the Managing Director for Infinitus Ventures, facilitating the early incubation, capital funding, and development of client companies. Mr. Dang also served as the Interim President and Chief Executive Officer of HepaLife Technologies,
1
--------------------------------------------------------------------------------
Inc. from October 13, 2009 through May 11, 2010. Mr. Dang was invited to join the Board of Directors due to his experience with public companies in the matters relating to business development, financial reporting and legal compliance.
Mr. Sidhu graduated from the British Columbia Institute of Technology with a Diploma in Corporate Finance in 1995. From 2002-2009, Mr. Sidhu was Vice-President of Montgomery Asset Management Corporation, a privately held firm providing financial and management consulting services to emerging growth corporations. Mr. Sidhu served as a member of the board of directors for U.S. Petroleum Corporation from August 2003 until August 2006. Since September 2008, Mr. Sidhu has been a director of Entheos Technologies, Inc. Mr. Sidhu was invited to join the Board of Directors due to his experience with public companies in the matters relating to business development, financial reporting and legal compliance.
On June 3, 2010 the Board of Directors also approved the terms of an Interim Executive Services Agreement between the Company and Mr. Dang (the “ Executive Services Agreement ”) pursuant to which Mr. Dang was appointed the Company’s President and Chief Executive Officer. Mr. Dang will receive a salary of $5,000 per month during the term of the Executive Services Agreement. The Executive Services Agreement may be terminated at any time with or without cause by the Company.
Phytomedical Techs (PYTO)
0.0450 +0.0050 (+12.50%) Wednesday, May. 5th, 2010
Detailed Opinion Show Signal Strength and Direction Composite Indicators Signal
Trend Spotter Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold
Short Term Indicators Average: 80% Buy
20-Day Average Volume - 27,750
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% Buy
50-Day Average Volume - 21,684
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% Buy
100-Day Average Volume - 36,347
Overall Average: 96% Buy
Price Support Pivot Point Resistance
0.045 0.045 0.045 0.045
Click on the indicator for a graphical interpretation, or visit the Education Center for information on the studies.
Barchart Marketplace
PhytoMedical Signs a Letter of Intent (LOI) with a Leading Chinese Research Services Organization to Advance Brain Cancer Dru...
Date : 04/15/2010 @ 8:00AM
Source : Business Wire
Stock : PhytoMedical Technologies, Inc. (PYTO)
Quote : 0.046 0.0 (0.00%) @ 2:36PM
PhytoMedical Signs a Letter of Intent (LOI) with a Leading Chinese Research Services Organization to Advance Brain Cancer Dru...
PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), a developer of ‘D11B’, an anti-cancer compound shown in early studies to inhibit the growth of difficult-to-treat brain cancer, today announced that the Company has entered into a Letter of Intent (LOI) with Shanghai Medicilon, Inc.
Founded in 2004, Shanghai Medicilon provides drug discovery contract research services to pharmaceutical and biotech companies around the world. Managed by a team of scientists formally of US-based pharmaceutical and biotechnology companies, Medicilon has been recognized as one of the top drug discovery contract research organizations in China. “An alliance with Shanghai Medicilon would be an important first step towards a long-term relationship, while expanding PhytoMedical’s developmental and commercialization capabilities on a broader geographic scale,” stated Dr. Lynch, President and CEO of PhytoMedical Technologies.
The overall goal envisioned is for Medicilon to conduct IND-enabling studies under current Good Laboratory Practice (cGLP) on PhytoMedical’s lead drug (D11B) at no cost to PhytoMedical. PhytoMedical and Medicilon will seek a Chinese pharmaceutical company to partner with us to financially support the services provided by Medicilon. In exchange for providing financial support, PhytoMedical will grant an exclusive license to the Chinese pharmaceutical partner to develop and market ‘D11B’ within China. As a service provider, Medicilon would not assume rights to any intellectual property in the collaboration. The Chinese partner and PhytoMedical will be responsible for submission of the IND package to their respective regulatory agencies.
“Our partnership with Medicilon is the first step towards expanding PhytoMedical’s global reach for our key anti-cancer drug candidate, D11B. We look forward to working with the Medicilon team to advance this very exciting anti-cancer compound,” stated Dr. Lynch.
PhytoMedical’s Brian Cancer Compound: Encouraging Early Results
Nearly two years ago, PhytoMedical initiated early testing of several anti-cancer compounds modeled on the science of bis-intercalation, a process by which compounds bind to the DNA of a cancer cell and prevent its replication, which in turn can eventually result in the death of the cancer cell.
Encouraging results from these important in vivo efficacy and toxicity tests were announced in February 2009, after the Company’s patented anti-cancer compound, ‘D11B’, was administered to specimens with difficult-to-treat human brain cancer (SF295 glioblastoma xenografts) and, according to researchers, proved to be least toxic and extremely effective in controlling the growth of SF295 human glioblastoma xenografts.
In all cases where specimens were treated for human glioblastoma brain cancer using PhytoMedical’s patented compound, researchers reported: a significant reduction in tumor size; prolonged lifespan of 46%-plus for the treated group versus the control group; notably enhanced chemotherapeutic effect of the compound; and even observed “tumor cured” in one of the specimens with the deadly glioblastoma cancer.
Interpreting the data collected from these important efficacy and toxicity tests, researchers favorably surmised that PhytoMedical’s anti-cancer compound may “…have its selectivity in killing SF295 human glioblastoma cells.” In contrast, broad anti-cancer treatments may be less effective and carry greater risks and side-effects than compounds with the key ability to selectively target and kill specific cancer cells -- an important consideration for the treatment of cancers in vital organs such as the brain, where glioblastoma is exhibited.
Glioblastoma is the most common and aggressive form of brain cancer, and is often highly-resistant to chemotherapy and other conventional treatments, meaning there is no current cure. Additionally, surgical removal such as complete resection of the tumor in combination with the most current and aggressive treatments continues to result in low survival rates.
About Shanghai Medicilon Inc.
Medicilon was founded in 2004 with the explicit purpose of providing fully integrated pharmaceutical services to the global pharmaceutical community. The company’s integrated drug discovery and development services are specially designed to help clients develop their research and discovery programs from the initial idea stage to the IND filing phase.
Shanghai Medicilon Inc. has been recognized as one of the top drug discovery contract research organizations (CROs) in China and is managed by a team of scientists with many years of experience in US-based pharmaceutical and biotechnology companies.
The company is headquartered in Zhangjiang High-Tech Park in Shanghai, China, with an additional US facility in Chicago. Medicilon occupies more than 200,000 square feet of lab space and has about 400 employees across biology, chemistry and preclinical research. Over 60% of the company’s employees have PhD and MS degrees, and more than 10% of scientists have advanced degrees and work experiences in western countries.
In 2008, Shanghai Medicilon spun off preclinical operations and formed a joint venture with MPI Research, Mattawan, Michigan. The new company is founded as Medicilon-MPI Preclinical Research and is located in Shanghai.
For additional information, please visit www.mediciloninc.com, www.medicilon-mpi.com
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.
For additional information, please visit www.PhytoMedical.com
To receive future press releases via email, please visit: http://www.phytomedical.com/investors.php
To view the full HTML text of this release, please visit:
http://www.phytomedical.com/IR/PressReleases/20100415.html
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
ELYSSE, Knew you'de be here to say HI, eventually. LOL
GLTY
I am still a shareholder and lurk here from time to time. lol
Hope this latest news turns into something big.
Nice to see some movement on the corporate side, now lets see the pps follow course.
volume decent today.
Wish we could get more interest here besides thee & me. LOL
Nice! I anticipate Dr. Lynch is also pursuing India.
Wolrd populations:
1 China 1,336,970,000 - 19.62%
2 India 1,179,618,000 - 17.31%
3 United States 309,075,000 - 4.54%
http://en.wikipedia.org/wiki/List_of_countries_by_population
NEW NEWS!
LOOKING UP....
PhytoMedical Signs a Letter of Intent (LOI) with a Leading Chinese Research Services Organization to Advance Brain Cancer Dru...
Date : 04/15/2010 @ 8:00AM
Source : Business Wire
Stock : PhytoMedical Technologies, Inc. (PYTO)
Quote : 0.05 0.022 (78.57%) @ 9:37AM
PhytoMedical Signs a Letter of Intent (LOI) with a Leading Chinese Research Services Organization to Advance Brain Cancer Dru...
PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), a developer of ‘D11B’, an anti-cancer compound shown in early studies to inhibit the growth of difficult-to-treat brain cancer, today announced that the Company has entered into a Letter of Intent (LOI) with Shanghai Medicilon, Inc.
Founded in 2004, Shanghai Medicilon provides drug discovery contract research services to pharmaceutical and biotech companies around the world. Managed by a team of scientists formally of US-based pharmaceutical and biotechnology companies, Medicilon has been recognized as one of the top drug discovery contract research organizations in China. “An alliance with Shanghai Medicilon would be an important first step towards a long-term relationship, while expanding PhytoMedical’s developmental and commercialization capabilities on a broader geographic scale,” stated Dr. Lynch, President and CEO of PhytoMedical Technologies.
The overall goal envisioned is for Medicilon to conduct IND-enabling studies under current Good Laboratory Practice (cGLP) on PhytoMedical’s lead drug (D11B) at no cost to PhytoMedical. PhytoMedical and Medicilon will seek a Chinese pharmaceutical company to partner with us to financially support the services provided by Medicilon. In exchange for providing financial support, PhytoMedical will grant an exclusive license to the Chinese pharmaceutical partner to develop and market ‘D11B’ within China. As a service provider, Medicilon would not assume rights to any intellectual property in the collaboration. The Chinese partner and PhytoMedical will be responsible for submission of the IND package to their respective regulatory agencies.
“Our partnership with Medicilon is the first step towards expanding PhytoMedical’s global reach for our key anti-cancer drug candidate, D11B. We look forward to working with the Medicilon team to advance this very exciting anti-cancer compound,” stated Dr. Lynch.
PhytoMedical’s Brian Cancer Compound: Encouraging Early Results
Nearly two years ago, PhytoMedical initiated early testing of several anti-cancer compounds modeled on the science of bis-intercalation, a process by which compounds bind to the DNA of a cancer cell and prevent its replication, which in turn can eventually result in the death of the cancer cell.
Encouraging results from these important in vivo efficacy and toxicity tests were announced in February 2009, after the Company’s patented anti-cancer compound, ‘D11B’, was administered to specimens with difficult-to-treat human brain cancer (SF295 glioblastoma xenografts) and, according to researchers, proved to be least toxic and extremely effective in controlling the growth of SF295 human glioblastoma xenografts.
In all cases where specimens were treated for human glioblastoma brain cancer using PhytoMedical’s patented compound, researchers reported: a significant reduction in tumor size; prolonged lifespan of 46%-plus for the treated group versus the control group; notably enhanced chemotherapeutic effect of the compound; and even observed “tumor cured” in one of the specimens with the deadly glioblastoma cancer.
Interpreting the data collected from these important efficacy and toxicity tests, researchers favorably surmised that PhytoMedical’s anti-cancer compound may “…have its selectivity in killing SF295 human glioblastoma cells.” In contrast, broad anti-cancer treatments may be less effective and carry greater risks and side-effects than compounds with the key ability to selectively target and kill specific cancer cells -- an important consideration for the treatment of cancers in vital organs such as the brain, where glioblastoma is exhibited.
Glioblastoma is the most common and aggressive form of brain cancer, and is often highly-resistant to chemotherapy and other conventional treatments, meaning there is no current cure. Additionally, surgical removal such as complete resection of the tumor in combination with the most current and aggressive treatments continues to result in low survival rates.
About Shanghai Medicilon Inc.
Medicilon was founded in 2004 with the explicit purpose of providing fully integrated pharmaceutical services to the global pharmaceutical community. The company’s integrated drug discovery and development services are specially designed to help clients develop their research and discovery programs from the initial idea stage to the IND filing phase.
Shanghai Medicilon Inc. has been recognized as one of the top drug discovery contract research organizations (CROs) in China and is managed by a team of scientists with many years of experience in US-based pharmaceutical and biotechnology companies.
The company is headquartered in Zhangjiang High-Tech Park in Shanghai, China, with an additional US facility in Chicago. Medicilon occupies more than 200,000 square feet of lab space and has about 400 employees across biology, chemistry and preclinical research. Over 60% of the company’s employees have PhD and MS degrees, and more than 10% of scientists have advanced degrees and work experiences in western countries.
In 2008, Shanghai Medicilon spun off preclinical operations and formed a joint venture with MPI Research, Mattawan, Michigan. The new company is founded as Medicilon-MPI Preclinical Research and is located in Shanghai.
For additional information, please visit www.mediciloninc.com, www.medicilon-mpi.com
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.
For additional information, please visit www.PhytoMedical.com
To receive future press releases via email, please visit: http://www.phytomedical.com/investors.php
To view the full HTML text of this release, please visit:
http://www.phytomedical.com/IR/PressReleases/20100415.html
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
NITE has been doing some odd things with the bid/ask lately. Would like to see them stay at or above the .05 ask
04/02/2010 4:11PM EDGAR Securities Registration Statement (S-1) USBB:PYTO
03/29/2010 6:06AM Form (8-K) Current report filing USBB:PYTO
03/22/2010 9:00AM BW PhytoMedical Announces the Appointment of Dr. James F. Lynch as President and CEO USBB:PYTO
PINK & ALL OTHERS WISHING TO CONTACT DR. LYNCH:
THE CONTACT IS THROUGH COMPANY IR
E MAIL TO BERICKSON@PHYTOMEDICAL.COM
She will make sure Dr Lynch receives the mail & he will respond to you.
Nice. Did you use the investors link on the PHYTO home page for contacting him or do you have a direct email for him.
Thanks
PINK, WILL TRY TO FIGGER OUT HOW TO DO SO. (puter retard, lol).
Sent a welcome note to Dr L and had nice reply and phone call.
Was not home to speak, but he left upbeat message. Is "excited (by the opportunity),& eager. There is a lot going on" and he is looking fwd to "moving ahead & creating value". Also mentioned his 23 years experinnce in the pharma field.
NOW looking for more dry powder. Current pps very compelling.
glty
Hey Chilar add me as an assistant to the board if you wish.
GLTY
Whirl, staying away as the stench remains in my nostrils. Do agree, however there might be $ to be made as the MM players haVE got a "play going".
My question is why, when there are "clean" shells to be had?
Answer: to run the pps and lay off all the elcheapo shares on the likes of brigunn. The run to 7's is a beautiful example.
This play is not over by a long shot, so GLTY.
BTW do some RR here, you might be made happy in the long term, (which IMO ain't that far in the future).
Post Unavailable
Pink, this is the drop of the first shoe. Next two, IMO will be the ones that make this puppy fly.
GLTY
Very interesting!
news!
PhytoMedical Announces the Appointment of Dr. James F. Lynch as President and CEO - Business Wire
The only thing, in the future, to get this out of the doldrums will be(good)news about the delivery system. Without that: more of the same. Guess I'm getting a bit discouraged.
Chilar-Happy New Years to you and those who are close to you also.
And lets toast to Pyto for a great year and other stocks which you, I and for that matter everyone has(my biggest position by far with my speculative money is in actc-a speculative but I think very good risk/reward ratio; it is a stem cell company).
Elysse, since it's only you & me here, best wishes to you (and your kitty) for a healthy, prosperous '10.
Think we'll both agree, the key to to the prosperous part, lies in the good hands of GW and the success of PYTO.
Elysse, GW returned call. As usual can't say anything, but working very hard. Nothing negative to report & no news.
Chilar-essentially the same kind of one day collapse occurred about a month ago, only to rebound.
Hopefully, the same thing will happen here.
Elysse, I have no Idea. No press release or info released by company.
Maybe tax sellers.
Just called GW to ask what the heck is going on. Left message. Don't anticipate he'll have anything to say.
Today was ugly to say the least-Chilar or anyone-do you know the reason behind all the selling? I couldn't find any news.
Hmmm. Someone picked up 125K @ .035 today. Cleaned the offer out.
HAPPY HOILDAYS TO ALL ! (EVEN IF IT'S TO MYSELF) lol
today someone bot 100k @.04. Nice to see a print like that.
Today's action demonstrates the explosive potential of a decent PR.
Spoke to Dr Gribble today re delivery system. It is not his expertise so no help. BUT, he is easily reached and suggested I talk to Doc Yang. Will see if he can be reached.
GLTA
Li-Xi Yang, MD, PhD: An Experienced Cancer Researcher
Dr. Li Xi Yang has more than 25 years of experience in the fields of cancer research, credited with many patents on anticancer compounds and publications in peer-reviewed journals. Dr. Yang completed his Postdoctoral Fellowship at Dartmouth Medical School, where he received his PhD in Pharmacology and Toxicology. He currently serves as Director of Radiation Oncology Residency Education and Senior Scientist at California Pacific Medical Center Research Institute. Dr. Yang also serves as Director of Academic Research at St. Mary’s Medical Center, San Francisco, CA. Dr. Li Xi Yang is an active member of several professional committees, including: Graduate Medical Education Committee, Institutional Review Board, and Institutional Animal Care and Use Committee.
nite pushing the mkt down. tax sellers getting raped.
(ME TOO)
Just occured to me that the dribs and drabs being sold these days, (now that the big seller is finished) is pbly the start of tax selling.
So, in the remainder of the month, no decent rally can be expected without news from the company.
Question of the week:
is no news good news?
or
is no news bad news?
elysse, You have no idea how much pain the move has caused me. All I can say is that GW says ONLY, "Still working on IV Formulation...."
My best guess is that once announced, pps will rebound. GW probably has been working very hard on some type of partnership arrangment to finance the next stages or maybe a sell out..
Heck, take a look at the deal ONYX PHARMA made with Proteolix. Perhaps I'm nuts, but I have very high expectations for PYTO.
GLTY
Thanks chilar.
It is worrisome to say the least see atock already at depressed level get literally sliced in half-I have to think that some folks know or at least think they know something negative which has not yet been disclosed(lets hope that it is the second choice with no basis).
Elysse, The meedting was to elect 3 directors and auditor. Nothing else.
I contacted GW to see if any other business would be discussed with intention of attending. Answer NEGATIVE,SO DIDN'T ATTEND.
Hopefully someone is not in the know re any negative problems concerning IV delivery system being worked upon by Latitude.
GLTY
I assume by looking at the stock price what whatever transpired today at that meeting was not "exactly" what was needed to send it into orbit.
ANNUAL MEETING TOMORROW (MON 23RD). no news will be forthcoming.
still working on IV delivery system.
pps in toilet!
Someone bot 100K today @.06.
Seller is still offering.
next week, i'm starting a new buying program.
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
342
|
Created
|
02/15/06
|
Type
|
Free
|
Moderators |
PhytoMedical
Contact:
PhytoMedical Technologies, Inc.
800-611-3388
www.PhytoMedical.com
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (Symbol: PYTO), together with its wholly owned subsidiaries, is an early stage research based biopharmaceutical company focused on the identification, acquisition, development and eventual commercialization of innovative plant derived pharmaceutical and nutraceutical compounds targeting cancer and diabetes.
An estimated 300 new drugs of world-wide importance, worth over $150 billion, still remain to be discovered amongst the 250,000 species of higher plants found on earth, of which less than 15% have been investigated for bioactive compounds.
Presently, twenty of the best selling drugs come from natural sources and 25% of all prescription drugs contain active compounds originally derived from or patterned after compounds derived from plants.
--------------------------------------------------------------------------------
Polyphenolic Compounds Increase Sugar Metabolism by a Factor of 20
Diabetes, which results from the body’s inability to produce enough insulin or use it efficiently, affects 18.2 million people in the United States, or 6.3% of the population (American Diabetes Association). The Centers for Disease Control and Prevention expects this number to rise to over 30 million by 2030. As the leading cause of end-stage renal disease, blindness and lower limb amputations, diabetes now costs the health care system over $132 billion each year.
While the causes of diabetes are not entirely clear, it is known that diet plays a key role in the prevention and cure of diabetes. In fact, research studies have shown that aqueous extracts of the most commonly consumed spice, cinnamon, improves the action of insulin and helps to control risk factors associated with diabetes including: glucose, insulin, cholesterol, triglycerides and related variables.
One study published in Diabetes Care, a journal of the American Diabetes Association, showed that as little as one gram a day of cinnamon – one-fourth of a teaspoon twice a day – can lower blood sugar by an average of 18 to 29 percent, triglycerides (fatty acids in the blood) by 23 to 30 percent, LDL (or “bad”) cholesterol by 7 to 27 percent and total cholesterol by 12 to 26 percent. Changes in HDL (“good”) cholesterol were not significant. Amazingly, the study found that the beneficial effects of cinnamon lasted for at least 20 days after people stopped taking it.
PhytoMedical is working towards synthesizing the active components found in cinnamon and characterizing their beneficial health effects.
--------------------------------------------------------------------------------
A New Class Of Antitumor Agents Designed To Bind To DNA And Kill Cancer Cells.
Cancer kills more than 1,500 Americans each day and is the second leading cause of death in America. Cancer is attributed to one in every four deaths nationally, and accounts for at least one in every ten dollars spent on healthcare. According to the American Cancer Society, 2006 estimates peg direct medical costs (the total of all health expenditures) at $78.2 billion and the total estimated cost of cancer (which includes indirect morbidity and mortality costs) at $206.3 billion.
Currently, at least 9.6 million Americans have been diagnosed with cancer according to National Cancer Institute estimates, with a staggering 1.4 million new cases expected by the end of this year. Despite spending more than $1 trillion to fight the disease in over three decades of research, over half a million Americans are expected to die of cancer this year, with the ‘lifetime risk’ of developing cancer still remaining high: In the US, men have a little less than 1 in 2 lifetime risk of developing cancer; for women the risk is a little more than 1 in 3.
In response, PhytoMedical is working in collaboration with scientists at Dartmouth College to develop new anti-cancer compounds. Dartmouth scientists have synthesized a novel class of antitumor agents with a cytotoxic affinity for cancer cells, designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or “double binding,” much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.
Working with Dartmouth scientists, PhytoMedical plans to improve upon the concept of bis-intercalation and will evaluate these new compounds against several different cancer cell lines, including prostate, lung, brain and bladder cancer.
http://www.PhytoMedical.com/Alerts-Index.asp
To view the full HTML text of this release, please visit:
http://www.PhytoMedical.com/IR/PressReleases/20060215-1.html
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |